Mumbai, July 20 -- Suven Life Sciences Ltd is on the precipice of its make-or-break moment.

The Hyderabad-based biopharmaceutical firm, focused on cracking the complex central nervous system (CNS) neuroscience puzzle, is expecting a breakthrough with its lead molecule by the end of 2026-27, with data to be released early next year.

The firm, which has invested about Rs.4,000 crore into the innovation pipeline, announced on 8 July that it completed a Rs.248.8 crore tranche of its 2025 preferential fundraising after all 17 non-promoter investors fully exercised their warrants, resulting in the issuance of 18.6 million equity shares. In total, it raised about Rs.858 crore through the issue.

It also announced plans to set up a wholly owned...